Autolus Therapeutics NasdaqGS:AUTL 주식 보고서 Autolus Therapeutics plc
NasdaqGS:AUTL 주식 보고서
AUTL 주식 개요 임상 단계의 바이오 제약 회사인 Autolus Therapeutics plc는 암 및 자가 면역 질환 치료를 위한 T세포 치료제를 개발하는 회사입니다.
Autolus Therapeutics plc 경쟁사 가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Autolus Therapeutics 과거 주가 현재 주가 US$3.51 52주 최고치 US$7.45 52주 최저치 US$3.06 베타 2.04 11개월 변경 -15.22% 3개월 변경 사항 -6.40% 1년 변경 사항 -4.10% 33년 변화 -48.31% 5년 변화 -70.55% IPO 이후 변화 -85.96%
최근 뉴스 및 업데이트
Autolus Therapeutics plc Announces FDA Approval of AUCATZYL for Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) Nov 09
New minor risk - Share price stability Nov 03
Autolus Therapeutics plc to Report Q3, 2024 Results on Nov 12, 2024 Oct 29
Autolus Therapeutics plc Appoints Matthias Will as Chief Development Officer, Effective September 30, 2024 Sep 19
Founder notifies of intention to sell stock Sep 18
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case Sep 06 더 많은 업데이트 보기
Autolus Therapeutics plc Announces FDA Approval of AUCATZYL for Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) Nov 09
New minor risk - Share price stability Nov 03
Autolus Therapeutics plc to Report Q3, 2024 Results on Nov 12, 2024 Oct 29
Autolus Therapeutics plc Appoints Matthias Will as Chief Development Officer, Effective September 30, 2024 Sep 19
Founder notifies of intention to sell stock Sep 18
Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case Sep 06
Autolus Therapeutics plc Presents Clinical Data Update at the Society of Hematologic Oncology Annual Meeting Aug 27
Consensus revenue estimates fall by 15% Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly? Aug 15
High number of new directors Aug 13
Autolus Therapeutics: Major Inflection Point On The Horizon Jul 31
Autolus Therapeutics plc to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
Autolus Therapeutics plc to Present Three Clinical Data Updates on Obecabtagene Autoleucel (obe-cel) in Relapsed/Refractory B-Cell Acute L-Cell Acute Lymphoblastic Leukemia (All) Patients at the 2024 European Hematology Association (EHA) Congress Jun 15
Autolus Therapeutics plc, Annual General Meeting, Jun 28, 2024 Jun 08
Autolus Therapeutics plc Presents Long-Term Follow-Up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obecabtagene Autoleucel in an Oral Presentation at ASCO Jun 01 Autolus Therapeutics plc announced delayed 10-Q filing May 15
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity May 14
High number of new directors May 01
Autolus Therapeutics plc to Report Q1, 2024 Results on May 14, 2024 Apr 24
Consensus revenue estimates decrease by 24%, EPS upgraded Apr 09 Autolus Therapeutics Announces Changes to its Board of Directors
New major risk - Shareholder dilution Mar 26
Consensus revenue estimates increase by 23% Mar 21
Full year 2023 earnings released: US$1.20 loss per share (vs US$1.57 loss in FY 2022) Mar 15
Autolus Therapeutics plc Receives Medicines and Healthcare Products Regulatory Agency (MHRA) Certification for Nucleus Commercial Manufacturing Site Mar 15
Autolus Therapeutics plc Receives Medicines and Healthcare Products Regulatory Agency (MHRA) Certification for Nucleus Commercial Manufacturing Site Mar 14
Autolus Therapeutics plc to Report Fiscal Year 2023 Results on Mar 14, 2024 Mar 01
Forecast to breakeven in 2026 Feb 12
New minor risk - Shareholder dilution Feb 10 Autolus Therapeutics plc has completed a Follow-on Equity Offering in the amount of $350.000016 million. Feb 09
Autolus Therapeutics plc announced that it expects to receive $220.000002 million in funding from BioNTech SE Feb 08
High number of new directors Feb 01
Consensus revenue estimates decrease by 11% Jan 25
Autolus Therapeutics plc Announces Acceptance of Biologics License Application for Obecabtagene Autoleucel as Potential Treatment for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Jan 22
Autolus Therapeutics plc Announces the Appointment of Robert W. Azelby to Its Board of Directors Jan 10
Autolus Therapeutics plc Announces Changes to Its Board of Directors, Effective December 31, 2023 Dec 22
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for Obecabtagene Autoleucel for Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Nov 29
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for Obecabtagene Autoleucel for Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Nov 28
Consensus estimates of losses per share improve by 10% Nov 09
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely Nov 06
Consensus revenue estimates increase by 11% Oct 25
Autolus Therapeutics plc to Report Q3, 2023 Results on Nov 02, 2023 Oct 12
Price target increased by 9.1% to US$7.98 Oct 02
Autolus Therapeutics plc Announces Data from Auto1/22 Trial in Pediatric Acute Lymphoblastic Leukemia Published in the Journal Blood Sep 06 Autolus Therapeutics plc Announces CFO Changes
Autolus Therapeutics Announces Publication in Nature Medicine on Obe-Cel in Pediatric Acute Lymphoblastic Leukemia Jul 07
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation Jun 26
Autolus Therapeutics plc Appoints Robert Iannone as Non-Executive Director Jun 22
Autolus Therapeutics plc Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma Jun 17
Autolus Therapeutics plc, Annual General Meeting, Jun 30, 2023 Jun 07
Consensus EPS estimates upgraded to US$0.87 loss Jun 07
Autolus Therapeutics plc Presents Positive Results from Pivotal Phase 2 Felix Study in Adult R/R B-All At Asco Jun 03
Consensus revenue estimates decrease by 55% May 13
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 07
Consensus revenue estimates increase by 65% May 06
Consensus revenue estimates decrease by 90%, EPS upgraded Mar 14
We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth Mar 09
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 09
Autolus Therapeutics plc to Report Q4, 2022 Results on Mar 07, 2023 Feb 16
Autolus Therapeutics plc Announces Board Changes Jan 21
Consensus forecasts updated Dec 18
Price target decreased to US$9.40 Dec 16
Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value? Dec 12
Consensus revenue estimates increase by 281% Dec 10
Autolus Therapeutics plc Announces Pivotal Phase 2 Felix Clinical Trial Has Met Primary Endpoint At Interim Analysis Dec 09
Price target decreased to US$10.19 Nov 16
Consensus revenue estimates increase by 979% Nov 10
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Nov 04
Autolus Therapeutics plc to Report Q3, 2022 Results on Nov 03, 2022 Oct 22
Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy Oct 12
Consensus revenue estimates fall by 40% Oct 06
Price target decreased to US$10.19 Oct 05
Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching Aug 17
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 05
Autolus Therapeutics Q2 2022 Earnings Preview Aug 03
Autolus Therapeutics plc to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Price target decreased to US$11.61 Jun 10
Autolus Therapeutics plc, Annual General Meeting, Jun 28, 2022 Jun 01
Consensus revenue estimates fall by 10% May 19
Consensus revenue estimates increase by 55% May 12
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 06 Autolus Therapeutics plc to Report Q1, 2022 Results on May 05, 2022
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation Apr 19
Consensus revenue estimates fall by 87% Mar 17
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 11
Autolus Therapeutics plc to Report Q4, 2021 Results on Mar 10, 2022 Feb 22
Consensus forecasts updated Dec 21
We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully Dec 15
Autolus Therapeutics plc Presents Positive Obecabtagene Autoleucel Data at 63rd ASH Annual Meeting & Exposition Dec 14
Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.72 loss in 3Q 2020) Nov 05 주주 수익률 AUTL US Biotechs US 마켓 7D 5.1% 3.7% 5.7% 1Y -4.1% 29.2% 36.9%
전체 주주 수익률 보기
수익률 대 산업: AUTL 지난 1년 동안 29.2 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: AUTL 지난 1년 동안 36.9 %를 반환한 US 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is AUTL's price volatile compared to industry and market? AUTL volatility AUTL Average Weekly Movement 10.2% Biotechs Industry Average Movement 9.5% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.3% 10% least volatile stocks in US Market 3.0%
안정적인 주가: AUTL 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: AUTL 의 주간 변동성 ( 10% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.
회사 소개 임상 단계의 바이오 제약 회사인 Autolus Therapeutics plc는 암 및 자가 면역 질환 치료를 위한 T 세포 치료제를 개발합니다. 이 회사의 임상 단계 프로그램에는 성인 ALL 치료를 위한 임상 1b/2상 시험 중인 CD19 표적 프로그램 T 세포 연구용 치료제인 오베카브타진 오토루셀(AUTO1)과 재발성 또는 불응성 ALL 소아 환자를 대상으로 임상 1상 시험 중인 AUTO1/22가 있습니다; TRBC1 및 TRBC2를 표적으로 하는 말초 T세포 림프종 치료를 위한 프로그램 T세포 연구용 치료제인 AUTO4, 신경모세포종 치료를 위해 개발 중인 GD2를 표적으로 하는 프로그램 T세포 연구용 치료제인 AUTO6NG, 다발골수종 치료를 위한 제품 후보물질인 AUTO8. 말초 T세포 림프종 치료를 위한 전임상 TRBC2 프로그램 T세포 제품 후보인 AUTO5를 개발하는 데 주력하고 있습니다.
자세히 보기 Autolus Therapeutics plc 기본 사항 요약 Autolus Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요? AUTL 기본 통계 시가총액 US$992.53m 수익(TTM ) -US$233.98m 수익(TTM ) US$10.50m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) AUTL 손익 계산서(TTM ) 수익 US$10.50m 수익 비용 US$137.14m 총 이익 -US$126.65m 기타 비용 US$107.34m 수익 -US$233.98m
주당 순이익(EPS) -0.88 총 마진 -1,206.51% 순이익 마진 -2,229.04% 부채/자본 비율 45.2%
AUTL 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
